Kalon Biological acquired by CalibreScientific Inc, in a deal advised by KBS Corporate.
Kalon Biological specialise in the development and production of medical diagnostic kits and commercial enzyme immunoassays EIA kits for the healthcare industry.
Kalon Biological are highly experienced within the research and development of medical kits, and operate a number of brands including; KalonBio, a specialist within in-vitro diagnostics, Clin-Tech, a stains, reagents and medical kits provider, and Microimmune, a provider of measles, mumps and rubella testing products to hospitals and other partners internationally.
The shareholders of Kalon Biological instructed KBS Corporate with the sale of their business ahead of retirement plans.
Once marketed, the opportunity attracted a wide range of interest, from both trade and private equity acquirers, with over 65 NDAs received.
The ultimate buyer was CalibreScientific Inc., part of StoneCalibre, a diversified global provider of reagents, tools and other products to the healthcare, laboratory and biopharmaceutical industries. Based in Los Angeles, the company work to solve and address issues within their markets and have a global reach to over 53 countries.
Through a strong acquisition strategy, CalibreScientific has seen recent levels of growth, and has diversified and expanded the product offering, as well as their market share across the world.
Fabio Rambelli, of KBS Corporate advised our clients on the deal, and commented, ‘I have enjoyed working on this deal and I feel the acquisition has been ideal for CalibreScientific, as a logical bolt-on opportunity, which will enable them to further increase market share within the life-sciences sector. The deal will also enable the shareholders at Kalon to begin their well-earned retirement. I wish all involved the best for the future.’